As of 2025-10-17, the EV/EBITDA ratio of Rapt Therapeutics Inc (RAPT) is -4.05. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. RAPT's latest enterprise value is 436.62 mil USD. RAPT's TTM EBITDA according to its financial statements is -107.73 mil USD. Dividing these 2 quantities gives us the above RAPT EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | - | - |
| Forward P/E multiples | - | - |
| Fair Price | - | - |
| Upside | - | - |
| Date | EV/EBITDA |
| 2025-10-16 | -4.05 |
| 2025-10-15 | -3.76 |
| 2025-10-14 | -3.45 |
| 2025-10-13 | -3.66 |
| 2025-10-10 | -3.72 |
| 2025-10-09 | -4.22 |
| 2025-10-08 | -4.13 |
| 2025-10-07 | -4.07 |
| 2025-10-06 | -4.20 |
| 2025-10-03 | -4.24 |
| 2025-10-02 | -4.08 |
| 2025-10-01 | -3.79 |
| 2025-09-30 | -3.57 |
| 2025-09-29 | -3.70 |
| 2025-09-26 | -3.66 |
| 2025-09-25 | -3.37 |
| 2025-09-24 | -3.29 |
| 2025-09-23 | -2.83 |
| 2025-09-22 | -2.70 |
| 2025-09-19 | -2.66 |
| 2025-09-18 | -2.76 |
| 2025-09-17 | -2.37 |
| 2025-09-16 | -2.32 |
| 2025-09-15 | -2.28 |
| 2025-09-12 | -2.10 |
| 2025-09-11 | -2.02 |
| 2025-09-10 | -1.78 |
| 2025-09-09 | -1.70 |
| 2025-09-08 | -1.65 |
| 2025-09-05 | -1.60 |
| 2025-09-04 | -1.57 |
| 2025-09-03 | -1.35 |
| 2025-09-02 | -1.43 |
| 2025-08-29 | -1.36 |
| 2025-08-28 | -1.37 |
| 2025-08-27 | -1.40 |
| 2025-08-26 | -1.34 |
| 2025-08-25 | -1.28 |
| 2025-08-22 | -1.35 |
| 2025-08-21 | -1.26 |
| 2025-08-20 | -1.20 |
| 2025-08-19 | -1.27 |
| 2025-08-18 | -1.41 |
| 2025-08-15 | -1.41 |
| 2025-08-14 | -1.34 |
| 2025-08-13 | -1.24 |
| 2025-08-12 | -1.28 |
| 2025-08-11 | -1.08 |
| 2025-08-08 | -1.12 |
| 2025-08-07 | -1.18 |